Kodiak Sciences Inc (KOD)
NASDAQ: KODHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
KOD stock chart
Technical analysisKey statistics
All statistics- Market cap
- $5.72B
- EPS (TTM)
- -$4.19
- Dividend yield
- None
- 52-week range
- 10.94 – 104.00
- Day range
- 89.91 – 94.24
- Volume / Avg
- 1.30M / 1.57M
- Beta
- —
- Shares outstanding
- 62.85M
- Next earnings
- Nov 12, 2026
52-week range
KOD stock today
Shares of Kodiak Sciences (KOD) finished lower on Oct 7 at $91.08, a drop of 1.36% or $1.26 per share, versus the S&P 500's 0.22% decline. At this level, KOD sits near the top of its 52-week range of $10.94 to $104.00: 12.4% below the high, set on Oct 1, 2026 and 732.5% above the low. KOD is up 225.8% year to date, outperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has gained 540.1%.
Kodiak Sciences has posted a net loss over the last twelve months (EPS of -$4.19), so its P/E ratio is not meaningful. Kodiak Sciences's next earnings report is expected on Nov 12, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About Kodiak Sciences
Company profileKodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that has complete Phase 3 clinical study to treat high prevalence retinal vascular diseases; and in Phase 3 clinical study for the treatment of diabetic retinopathy, wet age-related macular degeneration (AMD), retinal vein occlusion, and diabetic macular edema, as well as in Phase 2/3 clinical study to treat wet AMD. The company's preclinical stage product candidate includes KSI-501, an anti- interleukin-6 (IL-6) and VEGF-trap bispecific antibody biopolymer conjugate for high prevalence retinal vascular diseases; and KSI-101 (KSI-501P), a bispecific protein targeting IL-6 and VEGF developed for patients who have retinal fluid and inflammation.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Dr. Victor Perlroth M.D.
- Headquarters
- Palo Alto, CA
- Employees
- 141
- IPO year
- 2018
- Website
- kodiak.com
Financial highlights
Full financialsKodiak Sciences reported a net loss of $230.0 million, compared with a loss of $176.2 million a year earlier. Diluted earnings per share came in at -$4.32.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Growth | — | — | — | — | — |
| Net income | $-229.97M | $-176.21M | $-260.49M | $-333.82M | $-266.99M |
| EPS (diluted) | $-4.32 | $-3.35 | $-4.97 | $-6.39 | $-5.16 |
Analyst forecast
ForecastConsensus (7 analysts)
strong_buy
Avg. price target
$116.67+28.10%
- Strong buy 1
- Buy 5
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Nov 12, 2026
- Last reported (Q2 2026)
- Aug 13, 2026
- EPS actual vs est.
- $-1.05 vs —
KOD news
All KOD newsKodiak Sciences peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| IOVAIovance Biotherapeutics Inc. | 12.92 | -0.35% | $5.85B | vs KOD |
| CGONCG Oncology Inc. | 62.38 | -1.98% | $5.53B | vs KOD |
| SRRKScholar Rock Holding Corporation | 42.20 | -0.59% | $5.14B | vs KOD |
| CRSPCRISPR Therapeutics AG | 52.35 | -3.06% | $5.06B | vs KOD |
| IMVTImmunovant Inc. | 32.04 | -0.22% | $6.62B | vs KOD |
| ADPTAdaptive Biotechnologies Corporation | 26.28 | -2.30% | $4.19B | vs KOD |
| RLAYRelay Therapeutics Inc. | 17.95 | -4.22% | $3.93B | vs KOD |
| TARSTarsus Pharmaceuticals Inc. | 73.61 | -0.67% | $3.44B | vs KOD |
Indexes, lists and sector
Kodiak Sciences stock FAQ
What is Kodiak Sciences's stock price today?
KOD last traded at $91.08 as of Oct 7, 4:00 PM EDT, down 1.36% on the day. Prices are delayed at least 15 minutes.
When is Kodiak Sciences's next earnings date?
Kodiak Sciences is expected to report earnings on Thursday, November 12, 2026.
Who is Kodiak Sciences's CEO?
Dr. Victor Perlroth M.D. is the chief executive officer of Kodiak Sciences Inc, which has about 141 employees.
What is the KOD 52-week high?
The 52-week high for KOD is $104.00 and the 52-week low is $10.94. The stock is currently 12.4% below its high.